Tremfya

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
22-07-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
22-07-2022
Public Assessment Report Public Assessment Report (PAR)
20-07-2022

Active ingredient:

Guselkumab

Available from:

Janssen-Cilag International NV

ATC code:

L04AC

INN (International Name):

guselkumab

Therapeutic group:

Имуносупресори

Therapeutic area:

псориазис

Therapeutic indications:

Plaque psoriasis Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.

Product summary:

Revision: 8

Authorization status:

упълномощен

Authorization date:

2017-11-10

Patient Information leaflet

                                46
Б. ЛИСТОВКА
47
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
TREMFYA 100 MG ИНЖЕКЦИОНЕН РАЗТВОР В
ПРЕДВАРИТЕЛНО НАПЪЛНЕНА СПРИНЦОВКА
гуселкумаб (guselkumab)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ИЗПОЛЗВАТЕ ТОВА
ЛЕКАРСТВО, ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА
ЗА ВАС ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар, или
фармацевт или
медицинска сестра. Това включва и
всички възможни нежелани реакции,
неописани в
тази листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Tremfya и за какво се
използва
2.
Какво трябва да знаете, преди да
използвате Tremfya
3.
Как да използвате Tremfya
4.
Възможни нежелани реакции
5.
Как да съхранявате Tremfya
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА TREMFYA И ЗА КАКВО СЕ
ИЗПОЛЗВА
Tremfya съдържа активно
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Tremfya 100 mg инжекционен разтвор в
предварително напълнена спринцовка
Tremfya 100 mg инжекционен разтвор в
предварително напълнена писалка
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Tremfya 100 mg инжекционен разтвор в
предварително напълнена спринцовка
Всяка предварително напълнена
спринцовка съдържа 100 mg гуселкумаб
(guselkumab) в 1 ml
разтвор.
Tremfya 100 mg инжекционен разтвор в
предварително напълнена писалка
Всяка предварително напълнена
писалка съдържа 100 mg гуселкумаб (guselkumab)
в 1 ml
разтвор.
Гуселкумаб e изцяло човешки
имуноглобулин G1 ламбда (IgG1λ)
моноклонално антитяло
(mAb), получено в клетки от яйчници на
китайски хамстер (CHO) чрез
рекомбинантна ДНК
технология.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Инжекционен разтвор (инжекция)
Разтворът е бистър и безцветен до
светложълт.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Плаков псориазис
Tremfya е показан за лечение на умерен до
тежък псориазис с плаки при възрастни,
които са
подходящи за системна терапия.
Псориатичен артрит
Tremfya, приложен самостоятелно или в
комбинация с метотре
                                
                                Read the complete document

Similar products

Active ingredient Guselkumab

Guselkumab

ATC code L04AC

L04AC

Marketed by Janssen-Cilag International NV

Janssen-Cilag International NV

INN (International Name) guselkumab

guselkumab

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 22-07-2022
Summary of Product characteristics Summary of Product characteristics Spanish 22-07-2022
Public Assessment Report Public Assessment Report Spanish 20-07-2022
Patient Information leaflet Patient Information leaflet Czech 22-07-2022
Summary of Product characteristics Summary of Product characteristics Czech 22-07-2022
Public Assessment Report Public Assessment Report Czech 20-07-2022
Patient Information leaflet Patient Information leaflet Danish 22-07-2022
Summary of Product characteristics Summary of Product characteristics Danish 22-07-2022
Public Assessment Report Public Assessment Report Danish 20-07-2022
Patient Information leaflet Patient Information leaflet German 22-07-2022
Summary of Product characteristics Summary of Product characteristics German 22-07-2022
Public Assessment Report Public Assessment Report German 20-07-2022
Patient Information leaflet Patient Information leaflet Estonian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Estonian 22-07-2022
Public Assessment Report Public Assessment Report Estonian 20-07-2022
Patient Information leaflet Patient Information leaflet Greek 22-07-2022
Summary of Product characteristics Summary of Product characteristics Greek 22-07-2022
Public Assessment Report Public Assessment Report Greek 20-07-2022
Patient Information leaflet Patient Information leaflet English 22-07-2022
Summary of Product characteristics Summary of Product characteristics English 22-07-2022
Public Assessment Report Public Assessment Report English 20-07-2022
Patient Information leaflet Patient Information leaflet French 22-07-2022
Summary of Product characteristics Summary of Product characteristics French 22-07-2022
Public Assessment Report Public Assessment Report French 20-07-2022
Patient Information leaflet Patient Information leaflet Italian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Italian 22-07-2022
Public Assessment Report Public Assessment Report Italian 20-07-2022
Patient Information leaflet Patient Information leaflet Latvian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Latvian 22-07-2022
Public Assessment Report Public Assessment Report Latvian 20-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-07-2022
Public Assessment Report Public Assessment Report Lithuanian 20-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 22-07-2022
Public Assessment Report Public Assessment Report Hungarian 20-07-2022
Patient Information leaflet Patient Information leaflet Maltese 22-07-2022
Summary of Product characteristics Summary of Product characteristics Maltese 22-07-2022
Public Assessment Report Public Assessment Report Maltese 20-07-2022
Patient Information leaflet Patient Information leaflet Dutch 22-07-2022
Summary of Product characteristics Summary of Product characteristics Dutch 22-07-2022
Public Assessment Report Public Assessment Report Dutch 20-07-2022
Patient Information leaflet Patient Information leaflet Polish 22-07-2022
Summary of Product characteristics Summary of Product characteristics Polish 22-07-2022
Public Assessment Report Public Assessment Report Polish 20-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 22-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 22-07-2022
Public Assessment Report Public Assessment Report Portuguese 20-07-2022
Patient Information leaflet Patient Information leaflet Romanian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Romanian 22-07-2022
Public Assessment Report Public Assessment Report Romanian 20-07-2022
Patient Information leaflet Patient Information leaflet Slovak 22-07-2022
Summary of Product characteristics Summary of Product characteristics Slovak 22-07-2022
Public Assessment Report Public Assessment Report Slovak 20-07-2022
Patient Information leaflet Patient Information leaflet Slovenian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 22-07-2022
Public Assessment Report Public Assessment Report Slovenian 20-07-2022
Patient Information leaflet Patient Information leaflet Finnish 22-07-2022
Summary of Product characteristics Summary of Product characteristics Finnish 22-07-2022
Public Assessment Report Public Assessment Report Finnish 20-07-2022
Patient Information leaflet Patient Information leaflet Swedish 22-07-2022
Summary of Product characteristics Summary of Product characteristics Swedish 22-07-2022
Public Assessment Report Public Assessment Report Swedish 20-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 22-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 22-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 22-07-2022
Patient Information leaflet Patient Information leaflet Croatian 22-07-2022
Summary of Product characteristics Summary of Product characteristics Croatian 22-07-2022
Public Assessment Report Public Assessment Report Croatian 20-07-2022

Search alerts related to this product

Alerts Tremfya Guselkumab

Tremfya Guselkumab

View documents history

Documents history Documents history

Tremfya